Graft-vs-host disease remains a major complication after allogeneic hematopoietic SCT (HSCT) from an HLA identical donor. Development of GVHD results from donor T-cell responses to recipient mHAs due to polymorphisms between donor and recipient. Only a small number of human mHAs have been characterized although studies in mice suggest that a large number of them could be important in human transplantation. Human mHAs include some encoded by the Y chromosome genes and others encoded by autosomal genes. 1 Nevertheless, there is a complete lack of studies addressing the B-cell response to mHAs in GVHD.
Glutathione S-transferase T1 (GSTT1) is a drug-metabolizing enzyme that belongs to the GST superfamily and is involved in detoxification processes. GSTT1 is highly expressed in liver, kidney, small intestine and erythrocytes, and modulation of its expression is induced by substrates such as BU and CHOP. GSTT1 is encoded by a single-copy gene on the human chromosome 22, which is absent in 20% of the Caucasian population because of a deletion that removes the entire gene. 2 In the liver transplantation setting, we have reported that some GSTT1-negative patients who received a GSTT1-positive graft frequently develop a severe immune-mediated hepatitis, with the presence of anti-GSTT1 antibodies belonging to the IgG isotype. 3 Similarly, kidney transplants carried out with the same donor-recipient GSTT1 mismatch are, in a proportion of cases, associated with the presence of anti-GSTT1 antibodies, deposits of C4d and signs of chronic rejection. 4 We studied the role of GSTT1 as a potential new mHA in GVHD.
Here we describe a 33-year-old man who received an HSCT from his HLA-identical, multiparous, 31-year-old sister. The patient had been diagnosed with acute myelomonocytic Eo leukaemia, (CBFb-MYH11 fusion gene rearrangements and inv 16) and an allo-HSCT was indicated due to the presence of minimal residual disease after intensive chemotherapy. Conditioning regimen consisted of busulfan (16 mg/kg) and CHOP (120 mg/kg). A graft containing 11 Â 10 6 CD34 þ cells per kg of recipient weight was infused without manipulation and GVHD prophylaxis consisted of MTX on days þ 1 (15 mg/m 2 ); on days þ 3, þ 6 (10 mg/m 2 ); and CsA (2.5 mg/kg every 12 h). Neutrophil (40.5 Â 10 9 /l) and platelet (100 Â 10 9 /l) engraftment was observed on day þ 16 and þ 15, respectively. No signs of veno-occlusive disease were observed. One month after the transplant, he presented with raised levels of serum hepatic enzymes (alanine transaminase (ALT): 234 UI/l; aspartate aminotransferase (AST): 129 UI/l; g-GTP: 926 UI/l; alkaline phosphatase (ALP): 1918 UI/l; total bilirubin: 9.78 mg/100 ml) and a high eosinophil count in the peripheral blood. The patient was considered to have acute hepatic GVHD, without gut or skin involvement, and prednisone (1 mg/kg/d) was started on day þ 35. The liver function improved until it completely normalized on day þ 74 and prednisone was tapered. Five months after the transplant, the count of hepatic enzymes rose again and prednisone was reintroduced, starting at 1 mg/kg/d. No other signs of GVHD were seen. Autoimmune hepatitis was suspected. The patient had anti-nuclear as well as anti-GSTT1 antibodies. Additional antibody-markers of autoimmune hepatitis such as M2, liver kidney microsomal type 1 (LKM1), liver cytosol type 1 (LC-1), soluble liver antigen (SLA) or F-actin, were absent. The genotyping of DNA extracted from the peripheral blood before the transplant showed that the patient was heterozygous for the GSTT1 wild-type allele and his donor was GSTT1 homozygous null. At present, nine months after the transplant, the patient has converted peripheral blood cells to the homozygous GSTT1 null genotype, concurrent with a full donor chimerism status assessed by PCR-STR. To determine whether donor B cells produced the anti-GSTT1 antibodies, we tested a donor's serum sample and found that these antibodies were present at a titer of 1/40. GSTT1 genotyping was then extended to other family members: donor's husband was GSTT1 homozygous positive, therefore, their three children ought to be GSTT1 heterozygous þ /null. It is important to point out that some pregnant women with the GSTT1 null genotype produce anti-GSTT1 antibodies (of the IgG class) during pregnancy in the presence of a GSTT1-positive fetus, antibodies that may be maintained long after delivery. 5 Our hypothesis is that pre-sensitized anti-GSTT1 Ab-secreting cells were produced by the donor because of her exposure to fetal GSTT1 during pregnancies, then anti-GSTT1 memory B-cells once in the recipient were activated by the GSTT1 molecules expressed on the recipient's liver. Although presensitization is not necessary for a response like the one described here, this fact might have accelerated the process.
It is not the first time that a phase II enzyme is described as an mHA in GVHD. In 2003, a very interesting paper by Murata et al. 6 came out with the identification of one member of the UDP-glycosyltransferase 2 family (UGT2B17), as a new human mHA due to a homozygous deletion. They isolated CD8
þ CTLs from an allogeneic HLA identical HSCT recipient at the onset of acute GVHD involving the gastrointestinal tract, liver and skin. These CTLs were able to recognize UGT2B17-derived peptides presented by host APC. Our data add a new mHA as a potential target in gastrointestinal and hepatic GVHD mediated by anti-GSTT1 antibodies. This knowledge will set the stage for the inclusion of matched mHAs as a donor selection criterion and may provide support for differential diagnoses of hepatic abnormalities after allo-HSCT, such as drug-related, acute GVHD, veno-occlusive disease, autoimmune and viral, to select the optimal therapeutic option.
Patients showing an Ab-mediated alloimmune response to GSTT1 might be treated with the anti-CD20 MoAB, rituximab, although further studies will be required to evaluate the therapeutic function of rituximab in GVHD.
